A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOSE RANGING, ACTIVE AND PLACEBO CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY AND DURATION OF EFFECT OF RT002, A BOTULINUM TOXIN TYPE A FOR INJECTION, TO TREAT GLABELLAR LINES

Registry ID
RT002-CL002
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE2
Study type
INTERVENTIONAL
Sponsor
REVANCE THERAPEUTICS, INC.
Start date
2014-12-08
Last update
2014-11-21

Conditions

Related clinical trials

View on source registry